HDAC9 and Miyoshi myopathy: Interestingly, we identified that HMCLs and primary MM samples with a high TRC score were significantly more sensitive to the histone deacetylase (HDAC) inhibitor (HDACi) panobinostat, currently used for the treatment of patients with MM at relapse (supplemental Figure 12A-B).